Patrícia Silva, PhD, director of science content —

As cystic fibrosis causes excessive mucus production, respiratory infections are quite common among patients. The NHS UK website has some useful information to help distinguish between upper and lower respiratory tract infections. MORE: The danger of cross infections Upper respiratory tract infections Upper respiratory tract infections include things…

The Italian health insurance system has agreed to cover cystic fibrosis patients’ use of Vertex Pharmaceuticals‘ Orkambi (lumacaftor/ivacaftor). Those eligible for the Italian Medicines Agency coverage are patients 12 and older who have two copies of a particular mutation of the gene that is defective in the disease. That is the…

A first-grader with cystic fibrosis (CF), Conor Fink, inspired a close family friend to hop on his bicycle and spend his summer pedaling from the West to East Coast — Oregon to New York — to  raise money for Claire’s Place Foundation, a nonprofit helping children and families affected by the disease.

Books that deal with a disease that’s affecting you or your loved ones can be sometimes hard to read, but they can also remind you that you’re not alone. There are other people going through the same struggles as you are and they have found ways to cope. These books also…

Anthera Pharmaceuticals has received news that could help it accelerate patient enrollment in a Phase 3 clinical trial of Sollpura (liprotamase) as a treatment for a digestive disorder known as cystic fibrosis-triggered exocrine pancreatic insufficiency. The news is that a key Cystic Fibrosis Foundation committee approved the company’s trial design. The sign-off…

Synspira is planning to start a first, or Phase 1, clinical test of SNSP113, its therapeutic candidate for the treatment of cystic fibrosis (CF). The trial, expected to begin in 2018, is possible because of $8 million in funding Synspira received from a private investor, the company announced in a…

Celtaxsys announced it has completed enrollment of its Phase 2b clinical trial evaluating the company’s lead anti-inflammatory candidate, oral acebilustat, in adult patients with cystic fibrosis (CF). Acebilustat (formerly known as CTX-4430) is a once-daily, oral anti-inflammatory being evaluated for its safety and efficacy in treating diseases like CF. It is a new small…

Children with cystic fibrosis (CF) used the Spiro PD device by themselves to measure their lung function and take their breathing medication at home, according to its maker, PMD Healthcare. Use of the device led to better lung function, the company reported. It published its study in Global Pediatric Health under the…

The first of a series of young-adult fantasy books from Michael Seidelman features a teenage girl with cystic fibrosis (CF). “No One Dies in the Garden of Syn,” whose main character is Synthia “Syn” Wade, explores topics that let young readers know more about the disease. Seidelman will donate…

The first patient has been dosed in a Phase 2 clinical trial evaluating RPL554 as a treatment for cystic fibrosis (CF), according to its maker, Verona Pharma. RPL554 is a first-in-class drug candidate designed to inhibit the enzymes phosphodiesterase 3 and 4 (PDE3/PDE4). It has been shown to have…